DCE-MRI参数联合临床因素预测2018 FIGO IIICr期宫颈癌同步放化疗生存
本研究纳入117例2018 FIGO IIICr期宫颈癌患者,分析DCE-MRI参数(Ktrans、Kep、Ve)、ADC值及临床因素与同步放化疗后生存的关系。多因素分析显示IIIC2r期、Ktrans值和ADCmin值是PFS的独立预测因素;在IIIC1r亚组中,Ktrans、ADCmin及阳性淋巴结部位>2个为独立预后因素。
要点
- IIIC2r期、Ktrans值及ADCmin值是IIICr期宫颈癌同步放化疗后PFS的独立预测因素。
- IIIC1r亚组中,Ktrans、ADCmin及阳性淋巴结部位>2个为独立预后因素。
- DCE-MRI参数联合临床分期有助于评估预后并指导个体化治疗。
核心结论
- IIIC2r期、Ktrans值和ADCmin值是评估IIICr期宫颈癌生存和预后的最重要因素。
- 对于IIIC1r亚组,Ktrans、ADCmin值和阳性淋巴结部位>2个是独立预后因素。
研究设计与样本
- 47例出现结局事件(32例复发,15例死亡),中位PFS为35个月(范围6-68个月)。
- 分析原发肿瘤的ADC值(ADCmean、ADCmin、ADCmax)和DCE-MRI参数(Ktrans、Kep、Ve),并测量MRI和增强CT上可见淋巴结的短径。
- 采用Kaplan-Meier法比较PFS,Cox回归分析确定独立预测因素。
诊断标准与关键数值
- 多因素分析:IIIC2r期HR 2.701(95%CI 1.259-5.797,p=0.011),Ktrans HR 0.353(95%CI 0.189-0.659,p=0.001),ADCmin HR 0.423(95%CI 0.229-0.783,p=0.006)。
- 1年PFS率为90.4%,3年PFS率为74.4%。
临床应用与阅片要点
- 对于IIICr期宫颈癌患者,可结合FIGO分期(特别是IIIC2r)、DCE-MRI的Ktrans值和ADCmin值进行预后分层。
- 在IIIC1r亚组中,应关注Ktrans、ADCmin及阳性淋巴结部位>2个,以识别高危患者。
局限性
- 回顾性研究,样本量有限(117例),可能存在选择偏倚。
- 单中心研究,结果需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Combined clinical prognostic factors and magnetic resonance imaging (MRI) parameters on predicting the prognosis after concurrent chemo-radiotherapy (CCRT)in patients with 2018 International Federation of Gynecology and Obstetrics (FIGO) IIICr stage patients.
METHODS: A total of 117 patients with cervical cancer (2018 FIGO stage IIICr) who underwent CCRT were enrolled from Dec.2014 to Jul.2017. 47 patients developed outcome events, including 32 recurrences and 15 deaths. Clinical and MR parameters of primary tumors were analyzed, including apparent diffusion coefficient (ADC) values (ADCmean, ADCmin, and ADCmax) and dynamic contrast-enhanced MRI (DCE-MRI) parameters (Ktrans, Kep, Ve) were recorded. The short diameters of visible lymph nodes in the MRI and enhanced computed tomography (CT) images were measured. Progression-free survival (PFS) was compared by Kaplan-Meier analysis and independent predictors were identified using cox regression analysis.
RESULTS: The median PFS was 35 months (6-68 month). The 1-year and 3-year PFS rates were was 90.4 %, 74.4 %, respectively. Multivariate analysis showed that 2018 FIGOIIIC2r stage (HR 2.701,95 %CI1.259to. 5.797; p = 0.011), Ktrans(HR 0.353;95 %CI 0.189 to 0.659; p = 0.001) and ADCmin (HR0.423,95 %CI0.229to0.783; p = 0.006) were highly correlated with poor PFS.
CONCLUSION: In conclusion, we have identified IIIC2r stage, Ktrans value and ADCmin value as the most important factors in evaluating the survival rate and prognosis of patients with stage IIICr cervical cancer. For stage IIIC1r subgroup, Ktrans, ADCmin value and site of positive lymph node >2 were independent prognostic factors.
引用
- Qin F, Pang H, Ma J, et al. Combined dynamic contrast enhanced MRI parameter with clinical factors predict the survival of concurrent chemo-radiotherapy in patients with 2018 FIGO IIICr stage cervical cancer. Eur J Radiol. 2021. PMID: 34051683. doi:10.1016/j.ejrad.2021.109787
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。